Get the Stockscreener App
7.78
6.27%
-0.52
After Hours:
7.89
0.11
+1.41%
Capricor Therapeutics Inc stock is traded at $7.78, with a volume of 1.07M.
It is down -6.27% in the last 24 hours and up +5.35% over the past month.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
See More
Previous Close:
$8.30
Open:
$8.23
24h Volume:
1.07M
Relative Volume:
0.39
Market Cap:
$355.37M
Revenue:
$27.10M
Net Income/Loss:
$-24.31M
P/E Ratio:
-9.3735
EPS:
-0.83
Net Cash Flow:
$-33.33M
1W Performance:
-3.59%
1M Performance:
+5.35%
6M Performance:
-51.22%
1Y Performance:
+103.66%
1-Day Range:
$7.75
$8.305
1-Week Range:
$7.60
$9.43
52-Week Range:
$3.84
$23.40
Capricor Therapeutics Inc Stock (CAPR) Company Profile
Name
Capricor Therapeutics Inc
Sector
Industry
Phone
(310) 358-3200
Address
10865 ROAD TO THE CURE, SAN DIEGO, CA
Compare CAPR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CAPR
Capricor Therapeutics Inc
|
7.78 | 367.52M | 27.10M | -24.31M | -33.33M | -0.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
390.30 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
565.97 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
442.73 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
652.43 | 39.02B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
309.69 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-30-25 | Initiated | Alliance Global Partners | Buy |
| Jun-26-25 | Initiated | B. Riley Securities | Buy |
| May-20-25 | Initiated | Roth Capital | Buy |
| Oct-21-24 | Initiated | Piper Sandler | Overweight |
| May-17-24 | Initiated | Oppenheimer | Outperform |
| Jan-05-24 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-26-22 | Initiated | Ladenburg Thalmann | Buy |
| Dec-26-18 | Downgrade | Maxim Group | Buy → Hold |
| Jan-26-18 | Reiterated | H.C. Wainwright | Buy |
| Sep-15-17 | Reiterated | H.C. Wainwright | Buy |
| Feb-13-17 | Resumed | Rodman & Renshaw | Buy |
| Jul-06-16 | Resumed | H.C. Wainwright | Buy |
| Jun-15-16 | Initiated | ROTH Capital | Buy |
View All
Capricor Therapeutics Inc Stock (CAPR) Latest News
CAPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
CAPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - GlobeNewswire Inc.
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Capricor Therapeutics, Inc.(CAPR) Shareholders - Morningstar
Applying big data sentiment scoring on Capricor Therapeutics Inc.Swing Trade & Weekly Watchlist for Hot Stocks - Newser
Published on: 2025-08-14 06:24:14 - Newser
Capricor Therapeutics, Inc. Securities Fraud Class Action - GlobeNewswire
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit - PR Newswire
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Capricor - GlobeNewswire
CAPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces That Capricor Therapeutics, Inc. Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Capricor - Bluefield Daily Telegraph
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Capricor Therapeutics, Inc. – CAPR - FinancialContent
Best data tools to analyze Capricor Therapeutics Inc. stockWeekly Trend Report & AI Driven Stock Price Forecasts - Newser
What does recent volatility data suggest for Capricor Therapeutics Inc.Weekly Gains Report & Free Community Consensus Stock Picks - Newser
Lawsuit Alert: Investors who lost money with shares of Capricor - openPR.com
CAPR Stock News: Investors with Large Losses Should Contact Robbins LLP to Learn About Leading the Capricor Therapeutics, Inc. Class Action Lawsuit - PR Newswire
Capricor Therapeutics Inc (CAPR) Q2 2025 Earnings Report Preview: What To Expect - Yahoo Finance
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP - GlobeNewswire
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics - FinancialContent
CAPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - ACCESS Newswire
Capricor: Q2 Earnings Snapshot - Norwalk Hour
Levi & Korsinsky Reminds Capricor Therapeutics, Inc. - GlobeNewswire
Capricor Therapeutics Inc (CAPR) Q2 2025 Earnings Call Highlights: Navigating Challenges with ... - Yahoo Finance
Capricor Therapeutics: Q2 2025 Financial and Strategic Update - TipRanks
Capricor Therapeutics Q2 2025 Earnings Call Transcript - MarketBeat
Bragar Eagel & Squire, P.C. Urges Investors in XPLR - GlobeNewswire
Earnings call transcript: Capricor Therapeutics Q2 2025 sees widened loss, stock dips - Investing.com
Capricor Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
A mild market reaction for companies on Prasad’s return - BioWorld MedTech
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc.CAPR - PR Newswire
Vinay Prasad’s Return to FDA Sends Biotech Shares Tumbling - Bloomberg.com
Investors in Capricor Therapeutics, Inc. Should Contact The Gross Law Firm Before September 15, 2025 to Discuss Your RightsCAPR - MarketScreener
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - MarketScreener
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
Zurcher Kantonalbank Zurich Cantonalbank Purchases 3,162 Shares of Capricor Therapeutics, Inc. (NASDAQ:CAPR) - Defense World
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Capricor - GlobeNewswire
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Capricor Therapeutics, Inc. Investors to Secure - Bluefield Daily Telegraph
Custom watchlist performance reports with Capricor Therapeutics Inc.Monthly Trade Result and Signal Summary - Newser
Analyzing drawdowns of Capricor Therapeutics Inc. with statistical toolsTrade Safety Matrix for Conservative Traders - Newser
What earnings revisions data tells us about Capricor Therapeutics Inc.Value Investing Summary and Earnings Outlook - Newser
Why Capricor Therapeutics Inc. is moving todayVolume Spike Detection for Early Breakouts - Newser
Class Action Filed Against Capricor Therapeutics, Inc. - GlobeNewswire
Capricor stock rises on FDA meeting for rejected drug (CAPR) - Seeking Alpha
Duchenne Muscular Dystrophy Market Set to Grow Substantially Through 2034, DelveInsight Projects | Sarepta Therapeutics, Santhera Pharma, ReveraGen Biopharma, Pfizer, FibroGen, Capricor Therapeutics - Barchart.com
Capricor schedules FDA meeting on Duchenne therapy, delays earnings By Investing.com - Investing.com Canada
Capricor Therapeutics Announces Type A Meeting Scheduled with U.S. FDA | CAPR Stock News - GuruFocus
Class Action Filed Against Capricor Therapeutics, Inc. (CAPR) Seeking Recovery for InvestorsContact Levi & Korsinsky - PR Newswire
Capricor Therapeutics Schedules FDA Meeting to Discuss Deramiocel BLA for Duchenne Muscular Dystrophy - Quiver Quantitative
Capricor Therapeutics Announces Type A Meeting Scheduled with U.S. FDA - GlobeNewswire
Capricor's DMD Treatment Reaches Critical FDA Milestone: Type A Meeting to Discuss BLA Path - Stock Titan
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Receives Consensus Rating of “Buy” from Analysts - Defense World
Institutional scanner results for Capricor Therapeutics Inc.Risk Aware Swing Trade Analysis Insights - Newser
Capricor Therapeutics Inc Stock (CAPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
1.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):